Uroplasty (NYSE: UPI) and ConforMIS (NASDAQ:CFMS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitabiliy, earnings, institutional ownership and risk.
Profitability
This table compares Uroplasty and ConforMIS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Uroplasty | -31.58% | -87.33% | -60.82% |
| ConforMIS | -72.87% | -62.20% | -49.91% |
Analyst Recommendations
This is a breakdown of recent ratings for Uroplasty and ConforMIS, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Uroplasty | 0 | 0 | 0 | 0 | N/A |
| ConforMIS | 0 | 4 | 3 | 0 | 2.43 |
ConforMIS has a consensus target price of $8.25, indicating a potential upside of 120.00%. Given ConforMIS’s higher possible upside, analysts clearly believe ConforMIS is more favorable than Uroplasty.
Insider and Institutional Ownership
39.2% of ConforMIS shares are owned by institutional investors. 9.6% of ConforMIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Uroplasty and ConforMIS’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Uroplasty | N/A | N/A | N/A | N/A | N/A |
| ConforMIS | $80.10 million | 2.05 | -$55.08 million | ($1.36) | -2.76 |
Uroplasty has higher revenue, but lower earnings than ConforMIS.
Summary
ConforMIS beats Uroplasty on 7 of the 8 factors compared between the two stocks.
About Uroplasty
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
About ConforMIS
ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
